194 related articles for article (PubMed ID: 17305931)
21. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
22. The inability to take medications openly at home: does it help explain gender disparities in HAART use?
Sayles JN; Wong MD; Cunningham WE
J Womens Health (Larchmt); 2006 Mar; 15(2):173-81. PubMed ID: 16536681
[TBL] [Abstract][Full Text] [Related]
23. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).
Kapogiannis BG; Soe MM; Nesheim SR; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
Pediatrics; 2008 May; 121(5):e1229-39. PubMed ID: 18450865
[TBL] [Abstract][Full Text] [Related]
24. Abnormal haemoglobin levels in acute coronary syndromes.
Bindra K; Berry C; Rogers J; Stewart N; Watts M; Christie J; Cobbe SM; Eteiba H
QJM; 2006 Dec; 99(12):851-62. PubMed ID: 17121766
[TBL] [Abstract][Full Text] [Related]
25. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
El Amari EB; Toutous-Trellu L; Gayet-Ageron A; Baumann M; Cathomas G; Steffen I; Erb P; Mueller NJ; Furrer H; Cavassini M; Vernazza P; Hirsch HH; Bernasconi E; Hirschel B;
AIDS; 2008 May; 22(9):1019-28. PubMed ID: 18520345
[TBL] [Abstract][Full Text] [Related]
26. Cervico-vaginal dysplasia--papillomavirus-induced and HIV-1 infection: role of correlated markers for prognostic evaluation.
Pugliese A; Andronico L; Gennero L; Pagliano G; Gallo G; Torre D
Cell Biochem Funct; 2002 Sep; 20(3):233-6. PubMed ID: 12125100
[TBL] [Abstract][Full Text] [Related]
27. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
[TBL] [Abstract][Full Text] [Related]
28. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
29. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
Mocroft A; Ledergerber B; Zilmer K; Kirk O; Hirschel B; Viard JP; Reiss P; Francioli P; Lazzarin A; Machala L; Phillips AN; Lundgren JD;
AIDS; 2007 Sep; 21(14):1867-75. PubMed ID: 17721094
[TBL] [Abstract][Full Text] [Related]
30. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus.
López-Gatell H; Cole SR; Hessol NA; French AL; Greenblatt RM; Landesman S; Preston-Martin S; Anastos K
Am J Epidemiol; 2007 May; 165(10):1134-42. PubMed ID: 17339383
[TBL] [Abstract][Full Text] [Related]
31. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
[TBL] [Abstract][Full Text] [Related]
32. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
[TBL] [Abstract][Full Text] [Related]
33. Usefulness of hemoglobin and albumin as prognostic markers for highly active antiretroviral therapy for HIV-1 infection.
Chauhan NK; Vajpayee M; Singh A
Indian J Med Sci; 2011 Jul; 65(7):286-96. PubMed ID: 23422702
[TBL] [Abstract][Full Text] [Related]
34. Post-HAART tuberculosis in adults and adolescents with HIV in India: incidence, clinical and immunological profile.
Rajasekaran S; Raja K; Jeyaseelan L; Vijilat S; Priya K; Mohan K; Parvez A; Mahilmaran A; Chandrasekar C
Indian J Tuberc; 2009 Apr; 56(2):69-76. PubMed ID: 19810588
[TBL] [Abstract][Full Text] [Related]
35. Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer.
Lavolé A; Chouaïd C; Baudrin L; Wislez M; Raguin G; Pialoux G; Girard PM; Milleron B; Cadranel J
Lung Cancer; 2009 Sep; 65(3):345-50. PubMed ID: 19135758
[TBL] [Abstract][Full Text] [Related]
36. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
[TBL] [Abstract][Full Text] [Related]
37. Older age and the response to and tolerability of antiretroviral therapy.
Silverberg MJ; Leyden W; Horberg MA; DeLorenze GN; Klein D; Quesenberry CP
Arch Intern Med; 2007 Apr; 167(7):684-91. PubMed ID: 17420427
[TBL] [Abstract][Full Text] [Related]
38. Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death: a meta-regression analysis.
Mills EJ; Kelly S; Bradley M; Mollon P; Cooper C; Nachega J
HIV Med; 2008 Nov; 9(10):849-57. PubMed ID: 18795965
[TBL] [Abstract][Full Text] [Related]
39. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
40. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
